A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma

  • S.-M. B
  • J.H. L
  • S.-S. Y
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

The proteasome inhibitor bortezomib has demonstrated clinical activity in patients with multiple myeloma (MM). Adverse events, including thrombocytopenia and peripheral neuropathy, have affected 30% to 60% of patients overall, and interrupted therapy in 10% to 20%. No prior toxicity data are available for Asian patients who have used bortezomib for MM. We used National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, to review the clinical records of patients with an MM diagnosis from 25 centers in Korea. The included patients were treated with bortezomib alone or in combination with other agents, including thalidomide. Ninety-five MM patients were treated. The patients had a median age of 60 years (range, 42-77 years). The median number of previous treatments was 3 (range, 0-10), and 39% of the patients had been treated with 4 or more major classes of agents, including thalidomide (67%), and autologous stem cell transplantation (51%). Regimens included bortezomib only in 38 patients (40%), bortezomib plus dexamethasone in 34 patients (36%), and bortezomib plus a thalidomide-containing regimen in 23 patients (24%). The analysis of patient response to therapy revealed a complete response (CR) or a near-CR in 31 patients (33%) and a partial response in 30 patients (32%), for an objective response rate of 65% in 93 patients. The most common adverse events reported were thrombocytopenia (47%), sensory neuropathy (42%), anemia (31%), and leukopenia (31%). Thirteen patients (14%) stopped therapy because of adverse events (neuropathy, 8; infection, 4; diarrhea, 1). Neuropathy greater than grade 2 was more frequent in patients who received 4 or more prior therapy regimens (17/37) than in those who received 3 or fewer (14/58). In addition, therapy including thalidomide was significantly correlated with neuropathy of grades 1 to 3 (P = .001). We identified 6 therapy-related deaths (6%) within 20 days after the last dose of bortezomib. The causes of death were infection in 3 patients, disease progression in 2 patients, and suicide in 1 patient. The incidences of thrombocytopenia and neurotoxicity were similar; however, gastrointestinal toxicities were relatively low in Korean patients compared with those reported in Western studies. Significant neuropathy was associated with the number of prior regimens and combination with thalidomide. These findings provide useful information for clinicians and patients using bortezomib. ©2006 The Japanese Society of Hematology.

Author-supplied keywords

  • *bortezomib/ae [Adverse Drug Reaction]
  • *bortezomib/cb [Drug Combination]
  • *bortezomib/ct [Clinical Trial]
  • *bortezomib/dt [Drug Therapy]
  • *multiple myeloma/dt [Drug Therapy]
  • *multiple myeloma/th [Therapy]
  • Korea
  • adult
  • aged
  • anemia/si [Side Effect]
  • anorexia/si [Side Effect]
  • antineoplastic activity
  • article
  • autologous stem cell transplantation
  • cancer patient
  • cause of death
  • cisplatin/cb [Drug Combination]
  • cisplatin/ct [Clinical Trial]
  • cisplatin/dt [Drug Therapy]
  • clinical trial
  • constipation/si [Side Effect]
  • cyclophosphamide/cb [Drug Combination]
  • cyclophosphamide/ct [Clinical Trial]
  • cyclophosphamide/dt [Drug Therapy]
  • dehydration/si [Side Effect]
  • dexamethasone/cb [Drug Combination]
  • dexamethasone/ct [Clinical Trial]
  • dexamethasone/dt [Drug Therapy]
  • diarrhea/si [Side Effect]
  • disease course
  • dizziness/si [Side Effect]
  • doxorubicin/cb [Drug Combination]
  • doxorubicin/ct [Clinical Trial]
  • doxorubicin/dt [Drug Therapy]
  • drug withdrawal
  • dyspnea/si [Side Effect]
  • edema/si [Side Effect]
  • etoposide/cb [Drug Combination]
  • etoposide/ct [Clinical Trial]
  • etoposide/dt [Drug Therapy]
  • female
  • fever/si [Side Effect]
  • human
  • incidence
  • infection/si [Side Effect]
  • insomnia/si [Side Effect]
  • leukopenia/si [Side Effect]
  • major clinical study
  • male
  • multicenter study
  • nausea/si [Side Effect]
  • neurotoxicity/si [Side Effect]
  • pain/si [Side Effect]
  • peripheral neuropathy/si [Side Effect]
  • proteasome inhibitor/ae [Adverse Drug Reaction]
  • proteasome inhibitor/cb [Drug Combination]
  • proteasome inhibitor/ct [Clinical Trial]
  • proteasome inhibitor/dt [Drug Therapy]
  • rash/si [Side Effect]
  • retrospective study
  • sensory neuropathy/si [Side Effect]
  • suicide
  • thalidomide/cb [Drug Combination]
  • thalidomide/ct [Clinical Trial]
  • thalidomide/dt [Drug Therapy]
  • thrombocytopenia/si [Side Effect]
  • treatment response
  • vomiting/si [Side Effect]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Bang S.-M.

  • Lee J.H.

  • Yoon S.-S.

  • Park S.

  • Min C.-K.

  • Kim C.-C.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free